177 related articles for article (PubMed ID: 38684283)
21. Personalized targeted therapy for lung cancer.
Wu K; House L; Liu W; Cho WCS
Int J Mol Sci; 2012; 13(9):11471-11496. PubMed ID: 23109866
[TBL] [Abstract][Full Text] [Related]
22. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
Zhao Y; Wang H; He C
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758
[TBL] [Abstract][Full Text] [Related]
23. Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer.
Mukherji D; Spicer J
Expert Opin Investig Drugs; 2009 Mar; 18(3):293-301. PubMed ID: 19243280
[TBL] [Abstract][Full Text] [Related]
24. Molecular markers as therapeutic targets in lung cancer.
Tseng HH; He B
Chin J Cancer; 2013 Feb; 32(2):59-62. PubMed ID: 23369726
[TBL] [Abstract][Full Text] [Related]
25. Consecutive Emergence of Typical Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in a Patient With Metastatic Pulmonary Squamous Cell Carcinoma.
Yang CY; Hsieh MS; Liao WY; Shih JY; Yu CJ
J Oncol Pract; 2019 Feb; 15(2):115-118. PubMed ID: 30763203
[No Abstract] [Full Text] [Related]
26. Clairvoyance or reliable prediction of the future?
van Zandwijk N; van de Vijver MJ
Ann Oncol; 2007 Mar; 18(3):407-8. PubMed ID: 17322538
[No Abstract] [Full Text] [Related]
27. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Sequist LV
Oncologist; 2007 Mar; 12(3):325-30. PubMed ID: 17405897
[TBL] [Abstract][Full Text] [Related]
28. First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.
Park K; Yu CJ; Kim SW; Lin MC; Sriuranpong V; Tsai CM; Lee JS; Kang JH; Chan KC; Perez-Moreno P; Button P; Ahn MJ; Mok T
JAMA Oncol; 2016 Mar; 2(3):305-12. PubMed ID: 26720423
[TBL] [Abstract][Full Text] [Related]
29. Osimertinib effective in EGFR T790M-positive lung cancer.
Mayor S
Lancet Oncol; 2017 Jan; 18(1):e9. PubMed ID: 27989430
[No Abstract] [Full Text] [Related]
30. Dacomitinib: First Global Approval.
Shirley M
Drugs; 2018 Dec; 78(18):1947-1953. PubMed ID: 30506139
[TBL] [Abstract][Full Text] [Related]
31. [Treatment progress for EGFR wild-type advanced non-small cell lung cancer].
Ma F; Shi X; Meng W; Zhang J; Zhao L; He X; Zhao J
Zhongguo Fei Ai Za Zhi; 2014 Jul; 17(7):575-80. PubMed ID: 25034590
[TBL] [Abstract][Full Text] [Related]
32. Cross-over-it's a feature, not a bug.
Engelsberg A
Ann Oncol; 2015 Sep; 26(9):2000-2002. PubMed ID: 26078468
[TBL] [Abstract][Full Text] [Related]
33. Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review.
Marjanski T; Dziedzic R; Kowalczyk A; Rzyman W
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830123
[TBL] [Abstract][Full Text] [Related]
34. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.
Pao W; Chmielecki J
Nat Rev Cancer; 2010 Nov; 10(11):760-74. PubMed ID: 20966921
[TBL] [Abstract][Full Text] [Related]
35. Gefitinib for non-small cell lung cancer patients with liver cirrhosis.
Kim YH; Mio T; Mishima M
Intern Med; 2009; 48(18):1677-9. PubMed ID: 19755773
[TBL] [Abstract][Full Text] [Related]
36. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
[TBL] [Abstract][Full Text] [Related]
37. NSCLC drug targets acquire new visibility.
Friedrich MJ
J Natl Cancer Inst; 2011 Mar; 103(5):366-7. PubMed ID: 21357596
[No Abstract] [Full Text] [Related]
38. The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer.
Steuer CE; Khuri FR; Ramalingam SS
Cancer; 2015 Apr; 121(8):E1-6. PubMed ID: 25521095
[TBL] [Abstract][Full Text] [Related]
39. Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer.
Sartore-Bianchi A; Cerea G; Schiavetto I; Giannetta L; Ricotta R; Maugeri MR; Moroni M; Marrapese G; Siena S
Ann Oncol; 2006 Mar; 17 Suppl 2():ii49-51. PubMed ID: 16608982
[No Abstract] [Full Text] [Related]
40. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends.
Majeed U; Manochakian R; Zhao Y; Lou Y
J Hematol Oncol; 2021 Jul; 14(1):108. PubMed ID: 34238332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
